Venture Capital and Entrepreneurship in Heart Failure: A Review for Cardiologists

<h2>Abstract</h2> Collaboration between cardiologists, investigators, entrepreneurs, and investors is critical to addressing unmet clinical needs. This manuscript describes the significant impact of venture capital and entrepreneurship on advancing heart failure (HF) care, and how this ecosystem supports the development of novel diagnostics and therapeutics. The article provides an overview of the venture capital ecosystem and includes case studies within the medtech and biotech sectors, including the development of mavacamten (MyoKardia) and implantable hemodynamic monitoring (CardioMEMS), that illustrate successful collaborations that have improved HF patient care. By leveraging their clinical, scientific, and research expertise, HF cardiologists can foster the development of patient-centric solutions, thereby contributing to the expansion of management options for patients with HF.

Authors

Institutions

Publication Details

Journal
Journal of Cardiac Failure - Intersections
Published
2025-10-09
DOI
https://doi.org/10.1016/j.yjcafi.2025.08.014
Primary Topic
Cardiomyopathy and Myosin Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Venture Capital and Entrepreneurship in Heart Failure: A Review for Cardiologists

Peter Eckman, Ajay Srivastava, William T. Abraham, Anubodh S. Varshney et al.
Journal of Cardiac Failure - Intersections
Cardiomyopathy and Myosin Studies
article

Venture Capital and Entrepreneurship in Heart Failure: A Review for Cardiologists

Peter Eckman, Ajay Srivastava, William T. Abraham, Anubodh S. Varshney, Marc J. Semigran
article en

Abstract

<h2>Abstract</h2> Collaboration between cardiologists, investigators, entrepreneurs, and investors is critical to addressing unmet clinical needs. This manuscript describes the significant impact of venture capital and entrepreneurship on advancing heart failure (HF) care, and how this ecosystem supports the development of novel diagnostics and therapeutics. The article provides an overview of the venture capital ecosystem and includes case studies within the medtech and biotech sectors, including the development of mavacamten (MyoKardia) and implantable hemodynamic monitoring (CardioMEMS), that illustrate successful collaborations that have improved HF patient care. By leveraging their clinical, scientific, and research expertise, HF cardiologists can foster the development of patient-centric solutions, thereby contributing to the expansion of management options for patients with HF.

Journal of Cardiac Failure - IntersectionsVol. 2(1)
Allina Health (US), UC San Diego Health System (US), The Ohio State University Wexner Medical Center (US), Ulverscroft (United Kingdom) (GB), Broadview University (US), Stanford University (US)
Openalex Percentile: Top 57%
Cardiomyopathy and Myosin Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.